Enabling a healthy Start for vulnerable newborns

Citation for published version:
https://doi.org/10.1016/S0140-6736(20)32235-2

Digital Object Identifier (DOI):
10.1016/S0140-6736(20)32235-2

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Peer reviewed version

Published in:
The Lancet

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
If you are writing in response to published content in The Lancet, please type the full reference to that content here (for example: Cuzick J et al. Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial. Lancet 2020; 394: 117-22).

**Question**

If you are writing in response to published content in The Lancet, please type the full reference to that content here (for example: Cuzick J et al. Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial. Lancet 2020; 394: 117-22).

**Response**


**Author Comments:**

Thank you for considering this correspondence for publication in the Lancet, in response to the announcement of the Lancet Small Vulnerable Newborn Series. We believe the call for new reporting guidelines for perinatal studies will be of interest to the readership and support the call for global multidisciplinary approaches to research in maternal, fetal and newborn health.

We have listed and included author forms for eight co-authors, as we all made a significant contribution to this letter. Within our new iPOP (international Perinatal Outcomes in the Pandemic) Consortium we are keen to clearly demonstrate that we are committed to a team science approach, so would like all the contributors to be recognised on the correspondence if at all possible.

Yours Sincerely

Sarah Stock, Meredith Brockway, Helga Zoega, Jasper Been, Aziz Sheikh, Zulfiqar Bhutta, David Burgner, Meghan Azad.
The Lancet Small Vulnerable Newborn Series: Guidelines to Enable a Healthy Start

Sarah Stock PhD1*, Meredith Brockway PhD2, Helga Zoega PhD 3,4, Jasper V. Been PhD 5, Aziz Sheikh MD 1, Zulfiqar A Bhutta PhD 6, David P Burgner PhD 7,8, Meghan B. Azad PhD2

1 University of Edinburgh Usher Institute, Edinburgh, UK
2 Children’s Hospital Research Institute of Manitoba, Departments of Pediatrics and Child Health & Community Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada
3 Centre for Big Data Research in Health, Faculty of Medicine, UNSW Sydney, Australia
4 Centre of Public Health Sciences, Faculty of Medicine, University of Iceland, Iceland
5 Division of Neonatology, Department of Paediatrics, Erasmus MC - Sophia Children’s Hospital, University Medical Centre Rotterdam, Rotterdam, Netherlands
6 Centre for Global Child Health, The Hospital for Sick Children, Institute for Global Health and Development, The Aga Khan University, Pakistan
7 Murdoch Children’s Research Institute, Royal Children’s Hospital, Parkville, Australia
8 Department of Paediatrics, University of Melbourne, Parkville, Australia

*Corresponding author: NINE Edinburgh BioQuarter, 9 Little France Road, Edinburgh EH16 4UX, Scotland, UK sarah.stock@ed.ac.uk Telephone 07894629934

Word Count: 250 words
As co-leads of the new international Perinatal Outcomes in the Pandemic (iPOP) Consortium\(^1\) we are delighted that the Small and Vulnerable Newborn Series\(^2\) will focus cross-sector attention on the high burden of baby deaths (encompassing miscarriage, stillbirth and neonatal mortality) and disability (following preterm birth and low birthweight), which remains largely intractable with current siloed approaches.

iPOP, spanning 38 countries (and welcoming new collaborators\(^1\)), brings expertise in perinatology, epidemiology, environmental science, intersectional feminism, and data science\(^3\) within a collaborative, equitable and interdisciplinary framework. iPOP will investigate the effects of pandemic lockdowns on key perinatal outcomes, leveraging this natural experiment to understand possible mechanisms and inform interventions and policy. Conceptualisation of perinatal outcomes as a continuum, rather than discrete endpoints, is essential to this effort. The new Lancet Series is a timely initiative to catalyse this paradigm shift in the approach to perinatal research globally.

More generally, new reporting guidelines are needed to capture the complexity of perinatal studies, enabling assessment of data plausibility and completeness, and encouraging methodology which encompasses multiple (and competing) outcomes. Consensus guidance will support scientists, clinicians, reviewers and journal editors, driving up standards of research to benefit women and children. A pervasive culture remains that some perinatal data are too hard to collect and certain classifications of baby deaths (miscarriages, stillbirths) are less important to document. We call for standardised guidance for studies of perinatal outcomes as part of the Small and Vulnerable Newborn Series, to improve data quality, challenge these misconceptions, and support research transparency.
References


Acknowledgments

This work is supported by the Health Data Research UK International Covid-19 Data Alliance https://www.hdruk.ac.uk/covid-19/international-covid-19-data-alliance/, and the Canada Research Chairs Program. Sarah Stock is supported by a Wellcome Trust Clinical Career Development Fellowship (209560/Z/17/Z). Helga Zoega is an employee of the Centre for Big Data Research in Health, UNSW Sydney which has received funding from AbbVie Australia to conduct research, unrelated to iPOP and the present letter. AbbVie does not have any knowledge of, or involvement in, iPOP or the present letter. Meghan Azad holds the Canada Research Chair in the Developmental Origins of Chronic Disease and is a Fellow of the CIFAR Humans and the Microbiome Program. The funders had no involvement in the writing of this letter; or in the decision to submit this correspondence for publication

Declaration of interests
Sarah Stock reports grants from Wellcome Trust and Health Data Research UK, during the conduct of the study. Helga Zoega reports grants from AbbVie Australia outside the submitted work. Aziz Sheikh reports grants from Health Data Research UK, during the conduct of the study.

Author Contributions

JVB, AS, MBA, SJS, HZ, MB and DB contributed to the conception of the letter. SJS, MB, HZ, DB and MBA drafted the letter. ZAB, SJS, MB, HZ, MBA, JVB, AS and DB edited the letter. ZAB, SJS, MB, HZ, MBA, JVB, AS and DB all approved the final version to be published. SJS, MB, HZ, DB and MBA are co-leads of iPOP.